Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYVX59)

• DTT Name: Protein kinase C (PRKC)
• Gene Name: NO-GeName
• DTT Type: Clinical trial target; [1]
• Related Disease: Virus infection [ICD-11: 1A24-1D9Z]
• BioChemical Class: Kinase
• UniProt ID: NOUNIPROTAC
• TTD ID: T88318

Molecular Interaction Atlas (MIA) of This DTT

9 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[1]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[2]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[3], [4]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[6]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[8]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[9]
Safingol	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[10]

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[11]
Calphostin C	DM9X2D0	N. A.	N. A.	Terminated	[13]
Ro-31-8830	DMTIW6K	Inflammation	1A00-CA43.1	Terminated	[14]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rottlerin	DMOQ63E	Parkinson disease	8A00.0	Preclinical	[12]

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[15]
G6976	DMEZO4M	Solid tumour/cancer	2A00-2F9Z	Investigative	[16]
Staurosporine	DM0E9BR	Discovery agent	N.A.	Investigative	[13]

References

• [1] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [2] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [3] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [4] Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36.
• [5] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [6] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [9] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [10] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [11] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.
• [12] Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
• [13] Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
• [14] Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions. 1992 Sep;37(1-2):85-9.
• [15] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [16] The protein kinase C inhibitor G 6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5.